Citadel Advisors
IMNM icon

Citadel Advisors’s Immunome IMNM Stock Holding History

Citadel Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.75M Buy
224,079
+143,882
+179% +$3.08M ﹤0.01% 4811
2026
Q1 		$1.75M Sell
80,197
-1,660,508
-95% -$37M ﹤0.01% 6364
2025
Q4 		$37.4M Buy
1,740,705
+899,567
+107% +$15.8M 0.01% 1694
2025
Q3 		$9.85M Buy
+841,138
New +$8.37M ﹤0.01% 3298
2025
Q2 		– Sell
-340,103
Closed -$2.79M – 13720
2025
Q1 		$2.29M Buy
340,103
+244,237
+255% +$2.34M ﹤0.01% 5283
2024
Q4 		$1.02M Buy
+95,866
New +$1.16M ﹤0.01% 6968
2024
Q3 		– Sell
-4,167
Closed -$59.2K – 14697
2024
Q2 		$50.4K Buy
+4,167
New +$65.2K ﹤0.01% 11750
2024
Q1 		– Sell
-2,630
Closed -$53.4K – 14993
2023
Q4 		$28.1K Sell
2,630
-4,863
-65% -$40.4K ﹤0.01% 12318
2023
Q3 		$62.6K Buy
7,493
+6,394
+582% +$47K ﹤0.01% 11469
2023
Q2 		$8.69K Sell
1,099
-1,841
-63% -$10.1K ﹤0.01% 13302
2023
Q1 		$14.7K Buy
+2,940
New +$14.4K ﹤0.01% 13290
2022
Q3 		– Sell
-13,159
Closed -$61.7K – 13076
2022
Q2 		$42K Buy
+13,159
New +$47.9K ﹤0.01% 12034
2022
Q1 		– Sell
-21,216
Closed -$159K – 14058
2021
Q4 		$275K Buy
21,216
+2,868
+16% +$51.1K ﹤0.01% 11098
2021
Q3 		$447K Buy
+18,348
New +$320K ﹤0.01% 10152

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Citadel Advisors's IMNM Position: Q2 2026 in Review

Citadel Advisors increased its Immunome (IMNM) stake by 179% in Q2 2026, buying an estimated $3.08M and bringing the position to 224,079 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4811.

Citadel Advisors first reported a position in IMNM in Q3 2021 and has held it in 14 quarters since. The position peaked at $37.4M in Q4 2025. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Citadel Advisors held 224,079 shares of Immunome worth $4.75M as of Q2 2026.
  • Citadel Advisors bought 143,882 Immunome shares in Q2 2026, an estimated $3.08M.
  • Immunome made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4811 holding.
  • Citadel Advisors first reported a position in Immunome in Q3 2021 and has held it in 14 quarters since.
  • Citadel Advisors's Immunome position peaked at $37.4M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.